v3.25.3
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Cash flow from operating activities:    
Net loss for the year $ (26,556,140) $ (4,931,548)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization 15,271 15,271
Financial income (expenses), net (56,473)
Depreciation 91,356 68,626
Share-based compensation 776,879 1,804,078
Share of loss on equity investment 224,212 106,510
Change in fair value of warrants (758,364) (28,242,472)
Changes in assets and liabilities:    
Decrease (increase) in amounts receivable 733,629 (732,578)
Decrease in prepaid expenses 492,279 2,126,282
(Decrease) increase in accounts payable (3,887,078) 6,047,042
Increase (decrease) in accrued expenses and other payables 753,909 (387,339)
Net cash used in operating activities (28,170,520) (24,126,128)
Cash flow from investing activities:    
Purchase of property and equipment (456,801)
Purchase of short-term investments, net (7,316,000)
Equity investment in BC Therapeutics (330,000) (225,000)
Net cash used in investing activities (7,646,000) (681,801)
Cash flow from financing activities:    
Proceeds from exercise of warrants 821,015
Proceeds from issuance of shares, net of issuance costs 44,627,224 4,418,926
Net cash provided by financing activities 45,448,239 4,418,926
Increase in cash and cash equivalents 9,631,719 (20,389,003)
Cash and cash equivalents at beginning of year 862,089 21,251,092
Cash and cash equivalents at end of year $ 10,493,808 $ 862,089